Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations - Revision history

Jennelleh: Jennelleh moved page TestPCDtable to Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations without leaving a redirect

2021-04-22T21:42:28Z

Jennelleh moved page TestPCDtable to Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations without leaving a redirect

← Older revision	Revision as of 16:42, 22 April 2021
(No difference)

Kilannin.Krysiak: minor style changes

2020-11-08T03:28:12Z

minor style changes

← Older revision		Revision as of 22:28, 7 November 2020
Line 8:		Line 8:
	\| rowspan="11" \|'''Level 1'''		\| rowspan="11" \|'''Level 1'''

	well established evidence in NCCN guideline, WHO criteria, FDA-approved, COG recommendation, or based on large body of publications.		well established evidence in NCCN guideline,

			WHO criteria, FDA-approved, COG

			recommendation, or based on large body of publications.
	\|Hyperdiploidy (+3, +5, +7, +9, +11, +15, +21)		\|Hyperdiploidy (+3, +5, +7, +9, +11, +15, +21)
	\|Good prognosis		\|Good prognosis
Line 164:		Line 168:
	\|		\|
	\|}		\|}
	'''Table 2 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''~~. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis~~. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.

			'''Table 2 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Chromosome'''		\|'''Chromosome'''

Kilannin.Krysiak: Adding gene links

2020-11-08T02:06:28Z

Adding gene links

← Older revision		Revision as of 21:06, 7 November 2020
Line 15:		Line 15:
	\|t(4;14)		\|t(4;14)
	\|Poor prognosis, predicts bortezomib response		\|Poor prognosis, predicts bortezomib response
	\|''IGH''		\|''[[IGH]]''
	\|-		\|-
	\|t(6;14)		\|t(6;14)
	\|Good prognosis		\|Good prognosis
	\|''IGH''		\|''[[IGH]]''
	\|-		\|-
	\|t(14;16)		\|t(14;16)
	\|Poor prognosis		\|Poor prognosis
	\|''IGH''		\|''[[IGH]]''
	\|-		\|-
	\|t(11;14)		\|t(11;14)
	\|Good prognosis		\|Good prognosis
	\|''IGH''		\|''[[IGH]]''
	\|-		\|-
	\|t(14;20)		\|t(14;20)
Line 90:		Line 90:
	\|8q24.2+		\|8q24.2+
	\|Recurrent		\|Recurrent
	\|''MYC''		\|''[[MYC]]''
	\|-		\|-
	\|9p+		\|9p+
Line 98:		Line 98:
	\|del(10q23.31)		\|del(10q23.31)
	\|Recurrent		\|Recurrent
	\|''PTEN''		\|''[[PTEN]]''
	\|-		\|-
	\|11q+		\|11q+
Line 110:		Line 110:
	\|del(13q32.2)		\|del(13q32.2)
	\|Recurrent		\|Recurrent
	\|''TGDS''		\|''[[TGDS]]''
	\|-		\|-
	\|del(14q)		\|del(14q)
Line 154:		Line 154:
	\|22q21+		\|22q21+
	\|Associated with relapse		\|Associated with relapse
	\|''PRAME''		\|''[[PRAME]]''
	\|-		\|-
	\|del(X), X+, X CN-LOH		\|del(X), X+, X CN-LOH
Line 690:		Line 690:
	\| 17p13		\| 17p13
	\|Loss		\|Loss
	\|''[[ATP1B2]], ~~'''~~[[TP53]]~~'''~~, [[WRAP5]], [[EFNB3]]''		\|''[[ATP1B2]], [[TP53]], [[WRAP5]], [[EFNB3]]''
	\| Predictive & prognostic		\| Predictive & prognostic
	\|1		\|1

Kilannin.Krysiak: Added Table 1 commentary

2020-11-08T02:04:13Z

Added Table 1 commentary

← Older revision		Revision as of 21:04, 7 November 2020
Line 1:		Line 1:
	'''Table 1 - ~~Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH)~~ in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.		'''Table 1 - Clinically significant cytogenomic alterations in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. See Table 2 for references and Level 3 evidence. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Evidence Level'''		\|'''Evidence Level'''
Line 164:		Line 164:
	\|		\|
	\|}		\|}
	'''Table 1 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.		'''Table 2 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Chromosome'''		\|'''Chromosome'''

Kilannin.Krysiak: inserting Table 1 from the original paper

2020-11-08T01:55:03Z

inserting Table 1 from the original paper

Show changes

Kilannin.Krysiak: making style consistent, removing duplicates

2020-07-13T21:14:42Z

making style consistent, removing duplicates

← Older revision		Revision as of 16:14, 13 July 2020
Line 7:		Line 7:
	\|'''Significance (Recurrent, Diagnostic, Prognostic, Targeted treatment)'''		\|'''Significance (Recurrent, Diagnostic, Prognostic, Targeted treatment)'''
	\|'''Strength of Evidence (Level 1, 2, 3, see legend below table for criteria)'''		\|'''Strength of Evidence (Level 1, 2, 3, see legend below table for criteria)'''
	\|'''References'''		\|'''References'''
	\|-		\|-
	\| rowspan="9" \|1		\| rowspan="9" \|1
Line 33:		Line 33:
	\|1p13.2		\|1p13.2
	\|Loss		\|Loss
	\|~~MAG13(kinase)~~, BCL2 like and others		\|''[[MAGI3]]'', BCL2 like and others
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 120:		Line 120:
	\|4q35.1		\|4q35.1
	\|Loss		\|Loss
	\|''[[DCTD]], [[ING2]],'' and others		\|''[[DCTD]], [[ING2]]'' and others
	\|Recurrent		\|Recurrent
	\|2		\|2
Line 149:		Line 149:
	\|5p14.3		\|5p14.3
	\|Gain		\|Gain
	\|''CDH12~~,10~~''		\|''[[CDH10]], [[CDH12]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 163:		Line 163:
	\|5q13.2		\|5q13.2
	\|Loss		\|Loss
	\|''[[OCLN]], [[NAIP]]'', and others		\|''[[OCLN]], [[NAIP]]'' and others
	\|Recurrent		\|Recurrent
	\|2		\|2
	\|<ref name=":3" />		\|<ref name=":3" />
	\|-		\|-
	\| rowspan="7" \|6		\| rowspan="6" \|6
	\|6p		\|6p
	\|Gain		\|Gain
Line 210:		Line 210:
	\|3		\|3
	\|<ref name=":5" />		\|<ref name=":5" />
	\|-
	~~\|6q16.3~~
	~~\|Loss~~
	~~\|''[[COQR]], [[GRIK2]]''~~
	~~\|Recurrent~~
	\|3
	~~\|<ref name=":1" />~~
	\|-		\|-
	\| rowspan="4" \|7		\| rowspan="4" \|7
Line 235:		Line 228:
	\|7p15.2		\|7p15.2
	\|Gain		\|Gain
	\|''[[CBX3]], etc''		\|''[[CBX3]]'', etc
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 267:		Line 260:
	\|Recurrent		\|Recurrent
	\|3		\|3
	\|<ref name=":5" />		\|<ref name=":5" />
	\|-		\|-
	\|8q		\|8q
Line 285:		Line 278:
	\|8q24.3		\|8q24.3
	\|Gain		\|Gain
	\|''[[MAPK15]], [[TOP1MT]], [[CYP11B11]] (P450), ZNF41, ~~616~~, ~~707~~'' and ''~~ZNF517~~''		\|''[[MAPK15]], [[TOP1MT]], [[CYP11B11]] (P450), [[ZNF41]], [[ZNF517]], [[ZNF616]]'' and ''[[ZNF707]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 365:		Line 358:
	\|11q13.1/q13.4		\|11q13.1/q13.4
	\|Gain		\|Gain
	\|''[[SCYL1]], [[MAP3K11]], [[CCND1]], [[FGF4]], [[FGF3]], [[NUMA]],'' and ''[[RELT]]''		\|''[[SCYL1]], [[MAP3K11]], [[CCND1]], [[FGF4]], [[FGF3]], [[NUMA]]'' and ''[[RELT]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 576:		Line 569:
	\|19p/ 19p13		\|19p/ 19p13
	\|Gain		\|Gain
	\|''ICAM4,ICAM4, [[IBCL2L12]], [[TYK2]], [[IL2]],'' and ''[[DNMT1]]''		\|''ICAM4, ICAM4, [[IBCL2L12]], [[TYK2]], [[IL2]]'' and ''[[DNMT1]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 635:		Line 628:
	\| rowspan="8" \|X		\| rowspan="8" \|X
	\|X		\|X
	\|Gain/ Loss		\|Gain / Loss
	\|		\|
	\|Recurrent		\|Recurrent
Line 700:		Line 693:
	\|Genome wide load of CNA > 100Mb		\|Genome wide load of CNA > 100Mb
	\|		\|
	\|~~gain~~/~~loss~~		\|Gain / Loss
	\|		\|
	\|associated with significant change in GEP at relapse		\|associated with significant change in GEP at relapse

Kilannin.Krysiak: formatted references

2020-07-13T20:38:28Z

formatted references

Show changes

Kilannin.Krysiak: continued gene links

2020-07-13T20:28:45Z

continued gene links

← Older revision		Revision as of 15:28, 13 July 2020
Line 213:		Line 213:
	\|6q16.3		\|6q16.3
	\|Loss		\|Loss
	\|''COQR, GRIK2''		\|''[[COQR]], [[GRIK2]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 285:		Line 285:
	\|8q24.3		\|8q24.3
	\|Gain		\|Gain
	\|''MAPK15, TOP1MT, CYP11B11 (P450), ZNF41, 616, 707'' and ''ZNF517''		\|''[[MAPK15]], [[TOP1MT]], [[CYP11B11]] (P450), ZNF41, 616, 707'' and ''ZNF517''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 314:		Line 314:
	\|9q34.3		\|9q34.3
	\|Gain		\|Gain
	\|''ZNF79, CDK9, SET''		\|''[[ZNF79]], [[CDK9]], SET''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 336:		Line 336:
	\|10q23.31		\|10q23.31
	\|Loss		\|Loss
	\|''PTEN''		\|''[[PTEN]]''
	\|Recurrent		\|Recurrent
	\|2		\|2
Line 365:		Line 365:
	\|11q13.1/q13.4		\|11q13.1/q13.4
	\|Gain		\|Gain
	\|''SCYL1, MAP3K11, CCND1, FGF4, FGF3, NUMA,'' and ''RELT''		\|''[[SCYL1]], [[MAP3K11]], [[CCND1]], [[FGF4]], [[FGF3]], [[NUMA]],'' and ''[[RELT]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 379:		Line 379:
	\|11q22.1-q22.3		\|11q22.1-q22.3
	\|Homozygous Loss		\|Homozygous Loss
	\|BIRC3, BIRC2, MMP cluster		\|[[BIRC3]], [[BIRC2]], MMP cluster
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 401:		Line 401:
	\|12p13.1		\|12p13.1
	\|Loss		\|Loss
	\|''CDKN1B, APOLD1''		\|''[[CDKN1B]], [[APOLD1]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 416:		Line 416:
	\|13q14.11/q14.2		\|13q14.11/q14.2
	\|Loss		\|Loss
	\|''TNFSF11, RB1, P2RY5, RCBTB2''		\|''[[TNFSF11]], [[RB1]], [[P2RY5]], [[RCBTB2]]''
	\|Poor prognostic marker		\|Poor prognostic marker
	\|1		\|1
Line 423:		Line 423:
	\|13q32.2		\|13q32.2
	\|Loss		\|Loss
	\|''TGDS''		\|''[[TGDS]]''
	\|Recurrent		\|Recurrent
	\|2		\|2
Line 452:		Line 452:
	\|14q24.1-q24.3		\|14q24.1-q24.3
	\|Loss		\|Loss
	\|''MLH3''		\|''[[MLH3]]''
	\|Recurrent		\|Recurrent
	\|2		\|2
Line 459:		Line 459:
	\|14q32.32		\|14q32.32
	\|Homozygous Loss		\|Homozygous Loss
	\|''RCOR1, TRAF3, AMN, CDC42BPB''		\|''[[RCOR1]], [[TRAF3]], [[AMN]], [[CDC42BPB]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 474:		Line 474:
	\|15q24.1		\|15q24.1
	\|Gain		\|Gain
	\|''CYP11A1, ARID3B, CSK, etc.''		\|''[[CYP11A1]], [[ARID3B]], [[CSK]], etc.''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 482:		Line 482:
	\|16p11.2		\|16p11.2
	\|Loss		\|Loss
	\|''TP53TG3''		\|''[[TP53TG3]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 496:		Line 496:
	\|16q12.1-q12.2		\|16q12.1-q12.2
	\|Homozygous Loss		\|Homozygous Loss
	\|''CYLD, SALL1''		\|''[[CYLD]], [[SALL1]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 503:		Line 503:
	\|16q24.3		\|16q24.3
	\|Loss		\|Loss
	\|CBFA2T3 and others		\|''[[CBFA2T3]]'' and others
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 532:		Line 532:
	\|17p13		\|17p13
	\|Loss		\|Loss
	\|''ATP1B2, '''TP53''', WRAP5, EFNB3''		\|''[[ATP1B2]], '''[[TP53]]''', [[WRAP5]], [[EFNB3]]''
	\|Predictive & prognostic		\|Predictive & prognostic
	\|1		\|1
Line 576:		Line 576:
	\|19p/ 19p13		\|19p/ 19p13
	\|Gain		\|Gain
	\|''ICAM4,ICAM4, IBCL2L12, TYK2, IL2,'' and ''DNMT1''		\|''ICAM4,ICAM4, [[IBCL2L12]], [[TYK2]], [[IL2]],'' and ''[[DNMT1]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 628:		Line 628:
	\|22q21		\|22q21
	\|mostly Gain		\|mostly Gain
	\|''PRAME''		\|''[[PRAME]]''
	\|Recurrent, Associated with relapse		\|Recurrent, Associated with relapse
	\|2		\|2
Line 657:		Line 657:
	\|Xp22.33		\|Xp22.33
	\|Loss		\|Loss
	\|''SHOX, CRLF2, IL3RA''		\|''[[SHOX]], [[CRLF2]], [[IL3RA]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 678:		Line 678:
	\|Xq21.31-q21.32		\|Xq21.31-q21.32
	\|Loss		\|Loss
	\|''PABPC5, PCDHX''		\|''[[PABPC5]], [[PCDHX]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 685:		Line 685:
	\|Xq27.3-q28		\|Xq27.3-q28
	\|Gain		\|Gain
	\|''AFF2, MTMR1, etc''		\|''[[AFF2]], [[MTMR1]], etc''
	\|Recurrent		\|Recurrent
	\|3		\|3

Kilannin.Krysiak: adding gene links, partially complete

2020-07-13T20:03:37Z

adding gene links, partially complete

← Older revision		Revision as of 15:03, 13 July 2020
Line 12:		Line 12:
	\|1p32		\|1p32
	\|Loss		\|Loss
	\|''FAF1, CDKN2C''		\|''[[FAF1]], [[CDKN2C]]''
	\|Poor prognostic marker		\|Poor prognostic marker
	\|1, 2		\|1, 2
Line 19:		Line 19:
	\|1p22.2-p22.1		\|1p22.2-p22.1
	\|Loss		\|Loss
	\|''BARHL2, TGFBR3, and others; HSP90B3P, TGFER3, BRDT, EPHAX4, BTBD8''		\|''[[BARHL2]], [[TGFBR3]], and others; [[HSP90B3P]], [[TGFER3]], [[BRDT]], [[EPHAX4]], [[BTBD8]]''
	\|Prognostic		\|Prognostic
	\|1, 3		\|1, 3
Line 26:		Line 26:
	\|1p21.3		\|1p21.3
	\|Loss		\|Loss
	\|''SNX7''		\|''[[SNX7]]''
	\|Recurrent		\|Recurrent
	\|2		\|2
Line 40:		Line 40:
	\|1p12		\|1p12
	\|Loss		\|Loss
	\|''MAN1A2, FAM46C, GDAP2''		\|''[[MAN1A2]], [[FAM46C]], [[GDAP2]]''
	\|Recurrent		\|Recurrent
	\|2		\|2
Line 61:		Line 61:
	\|1q21.2-q23		\|1q21.2-q23
	\|Gain		\|Gain
	\|''CKS1B'' and ''ANP32E''		\|''[[CKS1B]]'' and ''[[ANP32E]]''
	\|Recurrent		\|Recurrent
	\|1		\|1
Line 106:		Line 106:
	\|4p16.3		\|4p16.3
	\|Loss		\|Loss
	\|''FGFR3'' and ''WHSC1''		\|''[[FGFR3]]'' and ''[[WHSC1]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 113:		Line 113:
	\|4p15.2		\|4p15.2
	\|Loss		\|Loss
	\|''LGI2, SEPSECS, PI4K2B'' and others		\|''[[LGI2]], [[SEPSECS]], [[PI4K2B]]'' and others
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 120:		Line 120:
	\|4q35.1		\|4q35.1
	\|Loss		\|Loss
	\|''DCTD, ING2,'' and others		\|''[[DCTD]], [[ING2]],'' and others
	\|Recurrent		\|Recurrent
	\|2		\|2
Line 163:		Line 163:
	\|5q13.2		\|5q13.2
	\|Loss		\|Loss
	\|''OCLN, NAIP'', and others		\|''[[OCLN]], [[NAIP]]'', and others
	\|Recurrent		\|Recurrent
	\|2		\|2
Line 192:		Line 192:
	\|6q11.1-q13		\|6q11.1-q13
	\|Gain		\|Gain
	\|''MTRNR2L9''		\|''[[MTRNR2L9]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 199:		Line 199:
	\|6q16.3		\|6q16.3
	\|Loss		\|Loss
	\|''COQR, GRIK2''		\|''[[COQR]], [[GRIK2]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 206:		Line 206:
	\|6q25.3		\|6q25.3
	\|Loss		\|Loss
	\|''IGFR3''		\|''[[IGFR3]]''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 235:		Line 235:
	\|7p15.2		\|7p15.2
	\|Gain		\|Gain
	\|''CBX3, etc''		\|''[[CBX3]], etc''
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 257:		Line 257:
	\|8p23.1		\|8p23.1
	\|Loss		\|Loss
	\|''DEFB4'' and others		\|''[[DEFB4]]'' and others
	\|Recurrent		\|Recurrent
	\|2		\|2
Line 264:		Line 264:
	\|8p21.3/p21.2		\|8p21.3/p21.2
	\|Loss		\|Loss
	\|''TNFRSF10B, DOCK5'' and others		\|''[[TNFRSF10B]], [[DOCK5]]'' and others
	\|Recurrent		\|Recurrent
	\|3		\|3
Line 278:		Line 278:
	\|8q24.2		\|8q24.2
	\|Gain/amplification and Loss		\|Gain/amplification and Loss
	\|''MYC''		\|''[[MYC]]''
	\|Recurrent		\|Recurrent
	\|2		\|2
Line 714:		Line 714:
	Level 2: emerging evidence (by one large study or multiple case reports)		Level 2: emerging evidence (by one large study or multiple case reports)

	Level 3: presumptive evidence (multiple case reports or expert opinion)<references />		Level 3: presumptive evidence (multiple case reports or expert opinion)

			==Reference==
			<references />

Kilannin.Krysiak: added intro and legend

2020-07-13T19:52:53Z

added intro and legend

← Older revision		Revision as of 14:52, 13 July 2020
Line 1:		Line 1:
			'''Table 1 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics.
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Chromosome'''		\|'''Chromosome'''
Line 158:		Line 159:
	\|Recurrent		\|Recurrent
	\|2		\|2
	\|24987674 (2014)<ref name=":1" /> 25145975 (2015)<ref name=":2" />		\|24987674 (2014)<ref name=":1" /> 25145975 (2015)<ref name=":2" />
	\|-		\|-
	\|5q13.2		\|5q13.2
Line 302:		Line 303:
	\|Recurrent		\|Recurrent
	\|2		\|2
	\|24987674 (2014)<ref name=":1" />, 25145975 (2015)<ref name=":2" />		\|24987674 (2014)<ref name=":1" />, 25145975 (2015)<ref name=":2" />
	\|-		\|-
	\|9q		\|9q
Line 469:		Line 470:
	\|Recurrent		\|Recurrent
	\|1		\|1
	\|24987674 (2014)<ref name=":1" />, 25145975 (2015)<ref name=":2" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" />,		\|24987674 (2014)<ref name=":1" />, 25145975 (2015)<ref name=":2" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" />,
	\|-		\|-
	\|15q24.1		\|15q24.1
Line 638:		Line 639:
	\|Recurrent		\|Recurrent
	\|2		\|2
	\|25145975 (2015)<ref name=":2" />, 22833442 (2012)<ref name=":7" />		\|25145975 (2015)<ref name=":2" />, 22833442 (2012)<ref name=":7" />
	\|-		\|-
	\|X		\|X
Line 705:		Line 706:
	\|27811368-(2016)<ref name=":9" />		\|27811368-(2016)<ref name=":9" />
	\|}		\|}
	<references />		cnLOH = copy neutral LOH, LOH = Loss of Heterozygosity, GEP = Gene Expression Profile

			'''Level of evidence:'''

			Level 1: well established evidence (in NCCN guideline, WHO criteria, FDA-approved, COG recommendation, or based on large body of publications)

			Level 2: emerging evidence (by one large study or multiple case reports)

			Level 3: presumptive evidence (multiple case reports or expert opinion)<references />